Transcatheter Tricuspid Valve Therapy

  • Dhaval Kolte
  • Sammy ElmariahEmail author
Valvular Heart Disease (J Dal-Bianco, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Valvular Heart Disease


Purpose of review

Despite the increasing prevalence of tricuspid regurgitation (TR) and its association with poor survival, isolated tricuspid valve (TV) surgery remains infrequent. To address this unmet clinical need, several less invasive transcatheter TV therapies have emerged as an alternative to surgery in high-risk patients with severe functional TR. The objective of this review is to summarize the current progress and future directions in the field of transcatheter TV therapies.

Recent findings

Transcatheter TV repair devices are aimed at improving leaflet coaptation either directly by bringing the leaflets together or indirectly by addressing the dilated annulus. Transcatheter TV replacement, on the other hand, can be orthotopic (implantation of prosthetic valve in an anatomically correct position in the tricuspid annulus) or heterotopic (implantation of prosthetic valve in a different anatomic location to counter the hemodynamic and clinical consequences of severe TR). Data from first-in-man and phase 1/2 clinical studies on the safety and efficacy of various transcatheter TV therapies appear promising.


Technological advancement and increased experience are anticipated to improve outcomes of transcatheter TV therapy in the coming years. Ongoing and future studies should focus on careful patient selection, optimal timing of intervention, and long-term clinical outcomes and device durability.


Valvular heart disease Transcatheter tricuspid valve therapy Tricuspid regurgitation Tricuspid valve 


Compliance with Ethical Standards

Conflict of Interest

Dhaval Kolte declares no potential conflicts of interest. Sammy Elmariah reports a grant from Edwards Lifesciences and personal fees from AstraZeneca and Medtronic.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Demir OM, Regazzoli D, Mangieri A, Ancona MB, Mitomo S, Weisz G, et al. Transcatheter tricuspid valve replacement: principles and design. Front Cardiovasc Med. 2018;5:129. Scholar
  2. 2.
    Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897–902.CrossRefGoogle Scholar
  3. 3.
    Topilsky Y, Maltais S, Medina IJ, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2018. Scholar
  4. 4.
    Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–9. Scholar
  5. 5.
    Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. 2006;132:1258–61. Scholar
  6. 6.
    Vassileva CM, Shabosky J, Boley T, Markwell S, Hazelrigg S. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database. J Thorac Cardiovasc Surg. 2012;143:1043–9. Scholar
  7. 7.
    Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Clinical and echocardiographic outcomes after surgery for severe isolated tricuspid regurgitation. J Thorac Cardiovasc Surg. 2013;146:278–84. Scholar
  8. 8.
    Kwon DA, Park JS, Chang HJ, Kim YJ, Sohn DW, Kim KB, et al. Prediction of outcome in patients undergoing surgery for severe tricuspid regurgitation following mitral valve surgery and role of tricuspid annular systolic velocity. Am J Cardiol. 2006;98:659–61. Scholar
  9. 9.
    Rodes-Cabau J, Hahn RT, Latib A, Laule M, Lauten A, Maisano F, et al. Transcatheter therapies for treating tricuspid regurgitation. J Am Coll Cardiol. 2016;67:1829–45. Scholar
  10. 10.
    •• Taramasso M, Alessandrini H, Latib A, Asami M, Attinger-Toller A, Biasco L, et al. Outcomes after current Transcatheter tricuspid valve intervention: mid-term results from the international TriValve Registry. JACC Cardiovasc Interv. 2018. This article describes the 30-day and 6-month outcomes of patients enrolled in a large, prospective international registry to evaluate the clinical applications of transcatheter tricuspid valve intervention with different devices.PubMedGoogle Scholar
  11. 11.
    Braun D, Orban M, Orban M, Hagl C, Massberg S, Nabauer M, et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. JACC Cardiovasc Interv. 2018;11:1790–2. Scholar
  12. 12.
    Nickenig G, Kowalski M, Hausleiter J, Braun D, Schofer J, Yzeiraj E, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation. 2017;135:1802–14. Scholar
  13. 13.
    Orban M, Besler C, Braun D, Nabauer M, Zimmer M, Orban M, et al. Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail. 2018;20:1055–62. Scholar
  14. 14.
    Braun D, Nabauer M, Orban M, Englmaier A, Rosler D, Hagl C, et al. One-year results of transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique. EuroIntervention. 2018;14:e413–5. Scholar
  15. 15.
    NCT03227757 Evaluation of Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE). C . 12-18-2018. 1-18-2019.Google Scholar
  16. 16.
    Praz F, Spargias K, Chrissoheris M, Bullesfeld L, Nickenig G, Deuschl F, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017;390:773–80. Scholar
  17. 17.
    Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407–8. Scholar
  18. 18.
    Puri R, Rodes-Cabau J. The FORMA repair system. Interv Cardiol Clin. 2018;7:47–55. Scholar
  19. 19.
    • Perlman G, Praz F, Puri R, Ofek H, Ye J, Philippon F, et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv. 2017;10:1994–2003. This multicenter study reports the 1-year clinical and echocardiographic outcomes of 18 patients treated with the FORMA system.CrossRefPubMedGoogle Scholar
  20. 20.
    NCT02471807. Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System. 3-22-2018. 1-18-2019.
  21. 21.
    NCT02787408. The SPACER trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System. 12-26-2017. 1-18-2019.
  22. 22.
    Schofer J, Bijuklic K, Tiburtius C, Hansen L, Groothuis A, Hahn RT. First-in-human transcatheter tricuspid valve repair in a patient with severely regurgitant tricuspid valve. J Am Coll Cardiol. 2015;65:1190–5. Scholar
  23. 23.
    Kay JH, Maselli-Campagna G, Tsuji KK. Surgical treatment of tricuspid insufficiency. Ann Surg. 1965;162:53–8.CrossRefGoogle Scholar
  24. 24.
    Ghanta RK, Chen R, Narayanasamy N, McGurk S, Lipsitz S, Chen FY, et al. Suture bicuspidization of the tricuspid valve versus ring annuloplasty for repair of functional tricuspid regurgitation: midterm results of 237 consecutive patients. J Thorac Cardiovasc Surg. 2007;133:117–26. Scholar
  25. 25.
    Besler C, Meduri CU, Lurz P. Transcatheter treatment of functional tricuspid regurgitation using the Trialign device. Interv Cardiol. 2018;13:8–13. Scholar
  26. 26.
    • Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. 2017;69:1795–806. This prospective, single-arm, multicenter, early feasibility study reports the 30-day outcomes of 15 patients treated with the Trialign device.CrossRefPubMedGoogle Scholar
  27. 27.
    NCT03225612. Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) (SCOUT-II). 2-7-2018. 1-18-2019.
  28. 28.
    Mangieri A, Lim S, Rogers JH, Latib A. Percutaneous tricuspid annuloplasty. Interv Cardiol Clin. 2018;7:31–6. Scholar
  29. 29.
    Rosser BA, Taramasso M, Maisano F. Transcatheter interventions for tricuspid regurgitation: TriCinch (4Tech). EuroIntervention. 2016;12:Y110–2. Scholar
  30. 30.
    NCT02098200. Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™ (PREVENT). 3-14-2018. 1-18-2019.
  31. 31.
    Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J. 2018. Scholar
  32. 32.
    Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy. 4-30-2018. Irvine, CA, Edwards Lifesciences, Inc. 1-18-2019.Google Scholar
  33. 33.
    Nickenig G. TRI-REPAIR: 30-day outcomes of transcatheter TV repair in patients with severe secondary tricuspid regurgitation. Transcatheter Cardiovascular Therapeutics 2017. 11-2-2017. Denver, CO. 11–2–2017.Google Scholar
  34. 34.
    NCT03382457. Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study. 8-15-2018. 1-19-2019.
  35. 35.
    Rogers JH, Boyd WD, Smith TW, Bolling SF. Early experience with Millipede IRIS transcatheter mitral annuloplasty. Ann Cardiothorac Surg. 2018;7:780–6. Scholar
  36. 36.
    First Clinical Tricuspid Bicuspidization Procedure Completed Using Micro Interventional Devices’ MIA Technology. Cardiac Interventions TODAY. 09-07-2017. 1-18-2019.
  37. 37.
    Rogers T, Ratnayaka K, Sonmez M, Franson DN, Schenke WH, Mazal JR, et al. Transatrial intrapericardial tricuspid annuloplasty. JACC Cardiovasc Interv. 2015;8:483–91. Scholar
  38. 38.
    Khan JM, Rogers T, Schenke WH, Greenbaum AB, Babaliaros VC, Paone G, et al. Transcatheter pledget-assisted suture tricuspid annuloplasty (PASTA) to create a double-orifice valve. Catheter Cardiovasc Interv. 2018;92:E175–84. Scholar
  39. 39.
    Hetzer R, Javier M, Delmo Walter EM. The double-orifice valve technique to treat tricuspid valve incompetence. J Heart Valve Dis. 2016;25:66–71.PubMedGoogle Scholar
  40. 40.
    Aboulhosn J, Cabalka AK, Levi DS, Himbert D, Testa L, Latib A, et al. Transcatheter valve-in-ring implantation for the treatment of residual or recurrent tricuspid valve dysfunction after prior surgical repair. JACC Cardiovasc Interv. 2017;10:53–63. Scholar
  41. 41.
    •• McElhinney DB, Aboulhosn JA, Dvir D, Whisenant B, Zhang Y, Eicken A, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57. This article reports the 3-year outcomes (death, reintervention, and valve-related adverse outcomes) of 306 patients enrolled in the Valve-in-Valve International Database (VIVID) Registry who underwent transcatheter tricuspid valve-in-valve or valve-in-ring replacement.CrossRefPubMedGoogle Scholar
  42. 42.
    Hahn RT, George I, Kodali SK, Nazif T, Khalique OK, Akkoc D, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging. 2018. Scholar
  43. 43.
    Navia JL, Kapadia S, Elgharably H, Harb SC, Krishnaswamy A, Unai S, et al. First-in-human implantations of the NaviGate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv. 2017;10.
  44. 44.
    Gavazzoni M, Pozzoli A, Zuber M, Ho EC, Tanner FC, Kapos I, et al. Single-center experience with catheter-based tricuspid valve replacement for tricuspid regurgitation: procedural and echocardiographic findings. JACC Cardiovasc Imaging. 2019. Scholar
  45. 45.
    Demir OM, Regazzoli D, Mangieri A, Ancona MB, Mitomo S, Weisz G, et al. Transcatheter tricuspid valve replacement: principles and design. Front Cardiovasc Med. 2018;5:129. Scholar
  46. 46.
    Weisz G (2018) TRISOL tricuspid valve replacement: a comprehensive solution for tricuspid regurgitation and RV dysfunction. The Structural Heart Diseas Summit 2018. 6-27-2018.Google Scholar
  47. 47.
    Lu F, Xu Z, Cao P, Chen Z, Lv S, Song Z. TCT-88 catheter-based tricuspid valve replacement via right atrium: an animal experimental study (abstr). J Am Coll Cardiol. 2017;70:B38–9.CrossRefGoogle Scholar
  48. 48.
    Lauten A, Ferrari M, Hekmat K, Pfeifer R, Dannberg G, Ragoschke-Schumm A, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J. 2011;32:1207–13. Scholar
  49. 49.
    Lauten A, Figulla HR, Unbehaun A, Fam N, Schofer J, Doenst T, et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv. 2018;11:e006061. Scholar
  50. 50.
    Figulla HR, Kiss K, Lauten A. Transcatheter interventions for tricuspid regurgitation - heterotopic technology: TricValve. EuroIntervention. 2016;12:Y116–8. Scholar
  51. 51.
    NCT02339974 Heterotopic implantation of the Edwards-Sapien transcatheter aortic valve in the inferior VEna cava for the treatment of severe tricuspid regurgitation (HOVER). 12-7-2018. 1-20-2019.
  52. 52.
    NCT02387697 Treatment of severe secondary TRIcuspid regurgitation in patients with advance heart failure with CAval vein implantation of the Edwards Sapien XT VALve (TRICAVAL). 9-18-2018. 1-20-2019.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Medicine, Massachusetts General HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations